AbbVie

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade AbbVie 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ABBV

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. 

CEO
Robert A. Michael
CEORobert A. Michael
Employees
57,000
Employees57,000
Headquarters
North Chicago, Illinois
HeadquartersNorth Chicago, Illinois
Founded
2011
Founded2011
Employees
57,000
Employees57,000

ABBV Key Statistics

Market cap
406.54B
Market cap406.54B
Price-Earnings ratio
106.78
Price-Earnings ratio106.78
Dividend yield
3.11%
Dividend yield3.11%
Average volume
5.84M
Average volume5.84M
High today
$232.32
High today$232.32
Low today
$218.01
Low today$218.01
Open price
$223.58
Open price$223.58
Volume
9.91M
Volume9.91M
52 Week high
$244.81
52 Week high$244.81
52 Week low
$181.73
52 Week low$181.73

Stock Snapshot

AbbVie(ABBV) stock is priced at $229.99, giving the company a market capitalization of 406.54B. It carries a P/E multiple of 106.78 and pays a dividend yield of 3.11%.

As of 2026-06-22, AbbVie(ABBV) stock has fluctuated between $218.01 and $232.32. The current price stands at $229.99, placing the stock +5.5% above today's low and -1.0% off the high.

The AbbVie(ABBV)'s current trading volume is 9.91M, compared to an average daily volume of 5.84M.

In the last year, AbbVie(ABBV) shares hit a 52-week high of $244.81 and a 52-week low of $181.73.

In the last year, AbbVie(ABBV) shares hit a 52-week high of $244.81 and a 52-week low of $181.73.

ABBV News

Nasdaq 4h
AbbVie's $10.9 Billion Apogee Deal Will Extend Its Immunology Dominance: Is It Time to Load Up on This Dividend King?

Key Points The deal gives the company a strong asset in zumilokibart, Apogee's very promising investigational drug. Apogee stockholders are to be paid $135.11...

AbbVie's $10.9 Billion Apogee Deal Will Extend Its Immunology Dominance: Is It Time to Load Up on This Dividend King?
Nasdaq 5h
Stock Market Today, June 22: Apogee Therapeutics Soars on AbbVie Cash Buyout Offer

Apogee Therapeutics (NASDAQ:APGE), a clinical-stage biologics company for inflammatory and immunology disorders, closed at $132.55, up 46.66%. AbbVie’s proposed...

Stock Market Today, June 22: Apogee Therapeutics Soars on AbbVie Cash Buyout Offer
Benzinga 11h
Apogee Therapeutics, Definium Therapeutics, Baldwin Insurance And Other Big Stocks Moving Higher On Monday

U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Monday. Shares of Apogee Therapeutics Inc (NASDAQ:APGE) rose sharply on Monda...

Apogee Therapeutics, Definium Therapeutics, Baldwin Insurance And Other Big Stocks Moving Higher On Monday

Analyst ratings

72%

of 32 ratings
Buy
71.9%
Hold
25%
Sell
3.1%

More ABBV News

TipRanks 13h
Early notable gainers among liquid option names on June 22nd

Notable gainers among liquid option names this morning include Super Micro (SMCI) $34.86 +4.20, ON Semiconductor (ON) $129.85 +8.23, Coinbase (COIN) $173.84 +10...

Benzinga 14h
AbbVie Expands Immunology Footprint With Apogee $11 Billion Acquisition

The deal strengthens its immunology portfolio and accelerates AbbVie’s expansion into respiratory diseases through a pipeline of clinical-stage therapies target...

AbbVie Expands Immunology Footprint With Apogee $11 Billion Acquisition
TipRanks 14h
AbbVie’s Strategic Pipeline and Immunology Expansion Support Buy Rating, Price Target Reaffirmed at $258

AbbVie, the Healthcare sector company, was revisited by a Wall Street analyst on June 19. Analyst Evan Seigerman from BMO Capital maintained a Buy rating on the...

TipRanks 14h
Apogee Therapeutics to Be Acquired by AbbVie

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new invest...

The Wall Street Journal 15h
AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

AbbVie has agreed to buy Apogee Therapeutics for about $10.9 billion in cash Brian Snyder / Reuters AbbVie ABBV -2.14 %decrease; down pointing triangle has agr...

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash
TipRanks 16h
AbbVie to acquire Apogee Therapeutics for $135.11 per share in cash, or $10.9B

AbbVie (ABBV) and Apogee Therapeutics (APGE) announced they have entered into a definitive agreement under which AbbVie will acquire Apogee and its diverse pipe...

TipRanks 16h
BTIG says others may be interested in Apogee Therapeutics

BTIG analyst Julian Harrison says AbbVie (ABBV) can leverage its existing dermatology channels and compete in atopic dermatitis beyond JAK inhibitors with an ac...

People also own

Based on the portfolios of people who own ABBV. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.